Drug companies rein in prices in response to President Trump's pharma pricing blueprint, HHS report says

Healthcare Finance: Pharmaceutical companies have been reining in prices since President Trump announced his drug pricing blueprint in May, according to Department of Health and Human Services Secretary Alex Azar.

There are 60 percent fewer brand drug price increases than last year and 54 percent more generic and brand drug price decreases than in 2017, HHS said in a report to mark 100 days since the blueprint's release.

Two drug companies are lowering prices or have rolled back increases; 13 have committed to price freezes for the rest of 2018 and four have canceled planned price increases, the report said.

Read article